Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4017MR)

This product GTTS-WQ4017MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4017MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5700MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ10071MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ3960MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ9002MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ12630MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ15095MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ10239MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ4865MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW